Literature DB >> 31610616

A preliminary report on the effect of gabapentin pretreatment on periprocedural pain during in-office posterior nasal nerve cryoablation.

Toby O Steele1,2, Steven G Hoshal1, Minji Kim3, Amarbir S Gill1, Machelle Wilson4, Lane D Squires1,2, E Bradley Strong1, Jeffrey D Suh3.   

Abstract

BACKGROUND: Posterior nasal nerve (PNN) cryoablation is a novel surgical technique to address allergic and nonallergic rhinitis. Periprocedural pain has been reported after PNN cryoablation and there are no standardized protocols for optimal in-office local anesthesia. This study sought to evaluate the effect of gabapentin on patient discomfort following in-office PNN cryoablation.
METHODS: Multi-institutional prospective analysis of patients undergoing in-office PNN cryoablation for allergic or nonallergic rhinitis between March 2018 and April 2019. Patients received local anesthesia with or without 600 mg oral gabapentin 1 hour preprocedure. Rhinitis diagnosis, demographics, and baseline disease-specific quality of life (mini-Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ] and Total Nasal Symptom Score [TNSS]) were recorded. Patient discomfort was measured by the pain visual analogue scale (VAS) posttreatment and rated 0 to 10 on an ordinal scale. Fisher's exact and Wilcoxon 2-sample tests were used to evaluate differences between the 2 groups.
RESULTS: A total of 26 patients were enrolled (gabapentin n = 15, control = 11). Baseline TNSS scores in the gabapentin vs control group were median [25th percentile to 75th percentile]) 10 (7.5 to 11.0) and 9 (6.0 to 10.0) (p = 0.35). Baseline Mini-RQLQ scores in gabapentin vs control groups were 3.21 (2.0 to 4.0) and 2.92 (2.78 to 4.35) (p = 0.51). The median VAS pain scores at 5, 20, and 30 minutes in the gabapentin vs control group were 0.0 (0.0 to 2.0) vs 3.0 (1.0 to 4.0), 2.0 (0.0 to 3.0) vs 8.0 (6.0 to 10.0), and 1.0 (0.0 to 1.0) vs 5.0 (4.0 to 6.0) (p = 0.02, p = 0.0043, and p = 0.003, respectively).
CONCLUSION: Preprocedure gabapentin significantly reduces immediate and delayed postprocedural patient discomfort following PNN cryoablation.
© 2019 ARS-AAOA, LLC.

Entities:  

Keywords:  ClariFix; cryoablation; gabapentin; posterior nasal nerve; rhinitis

Year:  2019        PMID: 31610616      PMCID: PMC7036325          DOI: 10.1002/alr.22456

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  19 in total

1.  Single dose of preoperative analgesia with gabapentin (600 mg) is safe and effective in monitored anesthesia care for nasal surgery.

Authors:  Zuleyha Kazak; N Meltem Mortimer; Sumru Sekerci
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-10       Impact factor: 2.503

2.  The effect of gabapentin on post-operative pain following tonsillectomy in adults.

Authors:  S Mikkelsen; K L Hilsted; P J Andersen; N-C Hjortsø; T P Enggaard; D G Jørgensen; M Hansen; J Henriksen; J B Dahl
Journal:  Acta Anaesthesiol Scand       Date:  2006-08       Impact factor: 2.105

3.  Allergic rhinitis (AR) is now estimated to affect some 1.4 billion people globally and continues to be on the rise. Editorial.

Authors:  Christina D Schwindt; Russell Settipane
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

4.  Cryosurgery on postganglionic fibers (posterior nasal branches) of the pterygopalatine ganglion for vasomotor rhinitis.

Authors:  A Terao; K Meshitsuka; H Suzaki; S Fukuda
Journal:  Acta Otolaryngol       Date:  1983 Jul-Aug       Impact factor: 1.494

5.  Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study.

Authors:  Chandra Kant Pandey; Deepa Vishwas Navkar; Pramod Janardan Giri; Mehdi Raza; Sanjay Behari; R B Singh; Uttam Singh; Prabhat Kumar Singh
Journal:  J Neurosurg Anesthesiol       Date:  2005-04       Impact factor: 3.956

Review 6.  Epidemiology of rhinitis: allergic and nonallergic.

Authors:  Russell A Settipane; David R Charnock
Journal:  Clin Allergy Immunol       Date:  2007

7.  Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.

Authors:  E F Juniper; A K Thompson; P J Ferrie; J N Roberts
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

8.  Idiopathic stabbing headache and experimental ice cream headache (short-lived headaches).

Authors:  H Macit Selekler; Faik Budak
Journal:  Eur Neurol       Date:  2003-11-18       Impact factor: 1.710

9.  Preemptive gabapentin reduces postoperative pain and opioid demand following thyroid surgery.

Authors:  Hussain Al-Mujadi; Abdul Rahman A-Refai; Mario Gueorguiev Katzarov; Najat Abbas Dehrab; Yatindra Kumar Batra; Abdul Rahim Al-Qattan
Journal:  Can J Anaesth       Date:  2006-03       Impact factor: 5.063

10.  Cryosurgical posterior nasal tissue ablation for the treatment of rhinitis.

Authors:  Peter H Hwang; Bryant Lin; Raymond Weiss; James Atkins; Jacob Johnson
Journal:  Int Forum Allergy Rhinol       Date:  2017-08-11       Impact factor: 3.858

View more
  3 in total

1.  Post-procedure Rhinitis After Use of Sedatives and Supplemental Nasal Oxygen.

Authors:  Sharmela Brijmohan; Tanganyika Barnes
Journal:  Cureus       Date:  2022-03-22

2.  Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis.

Authors:  Jivianne T Lee; Gregory M Abbas; Daniel D Charous; Pd Dr Med Mandy Cuevas; Prof Dr Med Önder Göktas; Patricia A Loftus; Nathan E Nachlas; Elina M Toskala; Jeremy P Watkins; Prof Dr Med Detlef Brehmer
Journal:  Am J Rhinol Allergy       Date:  2022-07-11       Impact factor: 2.300

3.  The Impact of Surgical Posterior Nasal Nerve Cryoablation on Symptoms and Disease-Specific Quality of Life in Patients With Chronic Rhinitis.

Authors:  Farrukh R Virani; Machelle D Wilson; Angela M Beliveau; Amarbir S Gill; E Bradley Strong; Toby O Steele
Journal:  Ear Nose Throat J       Date:  2021-06-15       Impact factor: 1.697

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.